Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults

Christopher Green, Elisa Scarselli, Merryn Voysey, Stefania Capone, Alessandra Vitelli, Alfredo Nicosia, Riccardo Cortese, Amber Thompson, Charles Sande, Catherine de Lara, Paul Klenerman, Andrew Pollard

Research output: Contribution to journal › Article › peer-review

35 Citations (Scopus)
80 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults'. Together they form a unique fingerprint.

Medicine & Life Sciences